Moreover, mice that showed complete responses following treatment with TransCon TLR7/8 Agonist and IL-2 did not develop palpable tumors following tumor rechallenge, indicating immunological memory developed with the combination treatment during the initial tumor challenge. Here, IL2 is linked to neoplasm.